Published July 30, 2021
| Version 2.0.0
Dataset
Open
Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Remdesivir for the treatment of COVID-19
Authors/Creators
- 1. University of Leipzig Medical Center, Leipzig, Germany
- 2. Department of Intensive Care Medicine, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Anaesthesiology and Intensive Care, Aachen, Germany
- 3. Department of Intensive Care Medicine, Medical Faculty, RWTH Aachen University, Aachen, Germany
- 4. Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Germany
- 5. Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
- 6. Cochrane Haematology, Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- 7. Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Description
Updated Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Remdesivir for the treatment of COVID-19.
Notes
Files
Files
(1.4 MB)
| Name | Size | |
|---|---|---|
|
md5:4ce75ef7dd2bd6ef69719fb56dadca25
|
444.9 kB | Download |
|
md5:3ed2143eb69d8f0897e9dab18af450c5
|
444.9 kB | Download |
|
2022-06-23_RoB 2 updated details for Cochrane Review 'Remdesivir for the treatment of COVID-19'.xlsm
md5:7ffaf146b55830668d33c8ba6d68cbed
|
542.6 kB | Download |
Additional details
Related works
- Is supplement to
- Journal article: 10.1002/14651858.CD014962 (DOI)